Prostate Cancer - Results from #26860

Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: Additional diagnoses and avoided deaths - Abstract October 28, 2011

Direct impact analysis of multi-leaf collimator leaf position errors on dose distributions in volumetric modulated arc therapy: A pass rate calculation between measured planar doses with and without the position errors - Abstract October 28, 2011

Hypofractionated radiotherapy with or without IGRT in prostate cancer: Preliminary report of acute toxicity - Abstract October 28, 2011

Multi-target drug discovery in anti-cancer therapy: Fragment-based approach toward the design of potent and versatile anti-prostate cancer agents - Abstract October 28, 2011

Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1c-T2N0M0 prostate cancer - Abstract October 28, 2011

Dietetic factors associated with prostate cancer. Protective effects of Mediterranean diet - Abstract October 27, 2011

Robot assisted laparoscopic prostatectomy. Striving for Trifecta outcomes in localised prostate cancer - Abstract October 27, 2011

Usefulness of CT-MRI fusion in radiotherapy planning for localized prostate cancer - Abstract October 27, 2011

Possibilities for surgical correction of an anastomotic stricture after radical prostatectomy - Abstract October 27, 2011

Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: Combined analysis of 4 phase II trials - Abstract October 27, 2011

Multimodal wavelet embedding representation for data combination (MaWERiC): Integrating magnetic resonance imaging and spectroscopy for prostate cancer detection - Abstract October 27, 2011

Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage C prostate cancer based on a planning protocol - Abstract October 27, 2011

A genome-wide survey over the ChIP-on-chip identified androgen receptor binding genomic regions identifies a novel prostate cancer susceptibility locus at 12q13.13 - Abstract October 27, 2011

There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies - Abstract October 27, 2011

Current treatment of locally advanced and metastatic prostate cancer - Abstract October 26, 2011

Focal therapy for prostate cancer: Opportunities and uncertainties - Abstract October 26, 2011

PSA regulates androgen receptor expression in prostate cancer cells - Abstract October 26, 2011

Secondary hormonal therapy in men with castration-resistant prostate cancer - Abstract October 26, 2011

Update on prostate cancer vaccines - Abstract October 25, 2011

Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer - Abstract October 25, 2011

Page 1344 of 1435